These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

711 related items for PubMed ID: 10088773

  • 1. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.
    Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D.
    Arthritis Rheum; 1999 Mar; 42(3):498-506. PubMed ID: 10088773
    [Abstract] [Full Text] [Related]

  • 2. Effects of interleukin 1 receptor antagonist alone and in combination with methotrexate in adjuvant arthritic rats.
    Bendele A, Sennello G, McAbee T, Frazier J, Chlipala E, Rich B.
    J Rheumatol; 1999 Jun; 26(6):1225-9. PubMed ID: 10381034
    [Abstract] [Full Text] [Related]

  • 3. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis.
    Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, Edwards CK.
    Arthritis Rheum; 2000 Dec; 43(12):2648-59. PubMed ID: 11145022
    [Abstract] [Full Text] [Related]

  • 4. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegård D, van den Berg WB.
    Arthritis Res; 1999 Dec; 1(1):81-91. PubMed ID: 11056663
    [Abstract] [Full Text] [Related]

  • 5. Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy.
    McComb J, Gould T, Chlipala E, Sennelo G, Frazier J, Kieft G, Seely J, Edwards CK, Bendele A.
    J Rheumatol; 1999 Jun; 26(6):1347-51. PubMed ID: 10381054
    [Abstract] [Full Text] [Related]

  • 6. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.
    Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, McCabe D.
    Arthritis Rheum; 2000 May; 43(5):1001-9. PubMed ID: 10817552
    [Abstract] [Full Text] [Related]

  • 7. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra.
    Joosten LA, Helsen MM, van de Loo FA, van den Berg WB.
    Arthritis Rheum; 2008 Feb; 58(2 Suppl):S110-22. PubMed ID: 18240201
    [Abstract] [Full Text] [Related]

  • 8. Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis.
    Gabay C, Marinova-Mutafchieva L, Williams RO, Gigley JP, Butler DM, Feldmann M, Arend WP.
    Arthritis Rheum; 2001 Feb; 44(2):451-62. PubMed ID: 11229477
    [Abstract] [Full Text] [Related]

  • 9. Adenoviral delivery of IL-1 receptor antagonist abrogates disease activity during the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice.
    Hur W, Cho ML, Yoon SK, Kim SY, Ju JH, Jhun JY, Heo SB, Moon YM, Min SY, Park SH, Kim HY.
    Immunol Lett; 2006 Aug 15; 106(2):154-62. PubMed ID: 16793145
    [Abstract] [Full Text] [Related]

  • 10. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist.
    Smeets RL, Joosten LA, Arntz OJ, Bennink MB, Takahashi N, Carlsen H, Martin MU, van den Berg WB, van de Loo FA.
    Arthritis Rheum; 2005 Jul 15; 52(7):2202-11. PubMed ID: 15986350
    [Abstract] [Full Text] [Related]

  • 11. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis.
    Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L, Senices M, Wu PW, Sibley B, Leathurby Y, Brown TP, Nickerson-Nutter C, Keith JC, Collins M.
    Arthritis Rheum; 2007 Apr 15; 56(4):1152-63. PubMed ID: 17393408
    [Abstract] [Full Text] [Related]

  • 12. Interleukin-1 receptor antagonist inhibits proteoglycan breakdown in antigen induced but not polycation induced arthritis in the rabbit.
    Arner EC, Harris RR, DiMeo TM, Collins RC, Galbraith W.
    J Rheumatol; 1995 Jul 15; 22(7):1338-46. PubMed ID: 7562769
    [Abstract] [Full Text] [Related]

  • 13. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models.
    Schett G, Middleton S, Bolon B, Stolina M, Brown H, Zhu L, Pretorius J, Zack DJ, Kostenuik P, Feige U.
    Arthritis Rheum; 2005 May 15; 52(5):1604-11. PubMed ID: 15880601
    [Abstract] [Full Text] [Related]

  • 14. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J, Schett G.
    Arthritis Rheum; 2004 Jan 15; 50(1):277-90. PubMed ID: 14730626
    [Abstract] [Full Text] [Related]

  • 15. The effect of recombinant human interleukin 1 receptor antagonist on the induction phase of antigen induced arthritis in the rabbit.
    Lewthwaite J, Blake SM, Hardingham TE, Warden PJ, Henderson B.
    J Rheumatol; 1994 Mar 15; 21(3):467-72. PubMed ID: 8006890
    [Abstract] [Full Text] [Related]

  • 16. Amelioration of accelerated collagen induced arthritis by a novel calcineurin inhibitor, ISA(TX)247.
    Maksymowych WP, Jhangri GS, Aspeslet L, Abel MD, Trepanier DJ, Naicker S, Freitag DG, Cooper BL, Foster RT, Yatscoff RW.
    J Rheumatol; 2002 Aug 15; 29(8):1646-52. PubMed ID: 12180723
    [Abstract] [Full Text] [Related]

  • 17. Arthritis in mice that are deficient in interleukin-1 receptor antagonist is dependent on genetic background.
    Zhou F, He X, Iwakura Y, Horai R, Stuart JM.
    Arthritis Rheum; 2005 Dec 15; 52(12):3731-8. PubMed ID: 16320323
    [Abstract] [Full Text] [Related]

  • 18. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
    Furst DE.
    Clin Ther; 2004 Dec 15; 26(12):1960-75. PubMed ID: 15823761
    [Abstract] [Full Text] [Related]

  • 19. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M, Zwicker M, Villiger PM.
    J Rheumatol; 2003 Jan 15; 30(1):28-35. PubMed ID: 12508386
    [Abstract] [Full Text] [Related]

  • 20. Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist.
    Lamacchia C, Palmer G, Seemayer CA, Talabot-Ayer D, Gabay C.
    Arthritis Rheum; 2010 Feb 15; 62(2):452-62. PubMed ID: 20112392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.